Home/Filings/4/0001387131-16-004984
4//SEC Filing

Adamis Pharmaceuticals Corp 4

Accession 0001387131-16-004984

CIK 0000887247operating

Filed

Apr 13, 8:00 PM ET

Accepted

Apr 14, 2:57 PM ET

Size

5.5 KB

Accession

0001387131-16-004984

Insider Transaction Report

Form 4
Period: 2016-04-13
Glover Eddie Wabern
CEO of U.S. Compounding, Inc.
Transactions
  • Award

    Common Stock

    2016-04-13+866,666866,666 total
Footnotes (1)
  • [F1]200,000 of these shares of common stock will be held in escrow until April 11, 2019 to satisfy the indemnification obligations of Mr. Glover under the Agreement and Plan of Merger, dated as of March 28, 2016 by and among Adamis Pharmaceuticals Corporation ("Adamis"), U.S. Compounding, Inc. ("USC"), and a wholly owned subsidiary of Adamis. In addition, 500,000 of these shares of common stock are subject to vesting under a milestone agreement entered into by Mr. Glover. Under the milestone agreement, one-third of these shares vest and are released to Mr. Glover annually over a period of three years from April 11, 2016 provided that Mr. Glover continues to be employed by USC or Adamis (with certain exceptions) as of the applicable vesting date.

Issuer

Adamis Pharmaceuticals Corp

CIK 0000887247

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000887247

Filing Metadata

Form type
4
Filed
Apr 13, 8:00 PM ET
Accepted
Apr 14, 2:57 PM ET
Size
5.5 KB